Perioperative dexamethasone in high-grade gliomas: the short-term benefits and long-term harms
Dexamethasone has been commonly given to patients with a presumed new GBM in relatively large doses (6-16 mg daily for Extras 1-2 weeks) since the 1960s without any rigorous evidence.This treatment with dexamethasone before the diagnosis and adjuvant therapy makes GBM patients unique compared to other newly diagnosed cancer patients.While dexametha